• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together almost 80 member organizations across the globe, united by a single purpose: driving global collaboration toward a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

Our Vision: A world free of ALS/MND

Our Aspiration: To drive global collaboration

Our Reach: We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose: Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

  • Bring focus to quality of life for PALS and their community: We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.
  • Include under-represented communities: By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.
  • Increase awareness of ALS/MND: By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.
  • Facilitate research coordination: By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.
  • Leverage collective capacity: By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.
  • Grow the community: By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Alliance Strategy 2026-2028: Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Annual Report 2024-2025: A review of the Alliance’s work and impact over the past year.

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Advisory Councils/Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Archives
    • Newsletters
    • Meetings
  • Awards

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • Andrietta, Italy

    Andrietta, Italy
    Andrietta

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Mark Miller, UK

    Mark Miller, UK

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Lombana, Spain

    Lombana, Spain

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • JP

    JP

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Ismail Gokcek, Turkey

    Ismail Gokcek, Turkey
    ismail_gokcek_alsmnd_tr

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Jon Newsome, USA

    Jon Newsome, USA

  • Jon Newsome, USA

    Jon Newsome, USA

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Den Haag, Netherlands

    Den Haag, Netherlands

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Mike Small, UK

    Mike Small, UK

  • Sally Pauls, USA

    Sally Pauls, USA

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Ian Roberts, Australia

    Ian Roberts, Australia

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Paul Launer, USA

    Paul Launer, USA

  • Zabun Nassar, England

    Zabun Nassar, England

  • Liam Dwyer, England

    Liam Dwyer, England

  • Richard Clark, New Zealand

    Richard Clark, New Zealand

  • Liam Dwyer, England

    Liam Dwyer, England

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • David Watson, Scotland

    David Watson, Scotland

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Willi Klein, UK

    Willi Klein, UK

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • David Solomon, UK

    David Solomon, UK

Learn more about the March of Faces

Footer

Subscribe to our Bi-monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login